RB1 and breast cancer: In contrast to tumors of other molecular subtypes, a study showed that about 30% of basal-like breast cancers concurrently exhibit overexpression of p16 and p53 immunoreactivity (pRB/p16þ/p53þ) and a lack of pRB expression [46].